| Literature DB >> 30875092 |
Izumi Nishimura1, Yuko Doi2, Norio Imai2, Mayumi Kawabe2, Yukinori Mera2, Takeo Shiina3.
Abstract
Although the likelihood of exposure to leaking intermediate frequency magnetic fields (MFs) from electronic devices, such as induction-heating and wireless power transfer systems, has increased, biological data assessing the health risks associated with human exposure remain insufficient. We examined the carcinogenicity of a 20 kHz MF, a typical frequency produced by induction-heating cookers, using a transgenic rasH2 mouse model. Twenty-five male and female CByB6F1-Tg(HRAS)2Jic mice were exposed to a 0.20 mT, 20 kHz MF (22 h/day) or sham-exposed for 26 weeks. As a positive control, 10 male and female rasH2 mice from the same batch were administered a single intraperitoneal injection of 75 mg/kg N-methyl-N-nitrosourea. A blinded histopathological evaluation was performed, and the same experiments were conducted twice, independently, to confirm the reproducibility of the results. Histopathological examination revealed that spontaneous neoplastic lesions, such as splenic hemangiosarcomas and gastric squamous cell papillomas, were less (1-3 per group) in the MF- and sham-exposed groups. The frequency of the neoplastic lesions was not significantly different between the groups. Eight to ten mice in each positive-control group exhibited malignant lymphoma. The outcomes were consistent between duplicated experiments, which indicates lack of carcinogenicity of 20 kHz MF in the rasH2 mouse model. Bioelectromagnetics.Entities:
Keywords: 20-kHz; health risk assessment; induction heating; short-term bioassay; wireless power transfer system
Mesh:
Year: 2019 PMID: 30875092 PMCID: PMC6594107 DOI: 10.1002/bem.22177
Source DB: PubMed Journal: Bioelectromagnetics ISSN: 0197-8462 Impact factor: 2.010
Survival Data of rasH2 Mice Exposed to a 20 kHz Magnetic Field
| Experiment I | Experiment II | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Sex | Group | Dose | No. of animals | Duration of experiment (weeks) | First dead mouse (weeks) | Terminal no. of surviving | First dead mouse (weeks) | Terminal no. of surviving | ||
| Male | Sham | 0 mT | 25 | 26 | 23 | 24 | (96%) | 21 | 24 | (96%) |
| MF Exp | 0.20 mT | 25 | 26 | N/A | 25 | (100%) | 16 | 23 | (92%) | |
| MNU | 75 mg/kg | 10 | 26 | 10 | 2 | (20%) | 10 | 0 | (0%) | |
| Female | Sham | 0 mT | 25 | 26 | 11 | 24 | (96%) | 26 | 24 | (96%) |
| MF Exp | 0.20 mT | 25 | 26 | N/A | 25 | (100%) | 15 | 22 | (88%) | |
| MNU | 75 mg/kg | 10 | 26 | 12 | 0 | (0%) | 11 | 0 | (0%) | |
Sham, sham‐exposed; MF Exp, magnetic field‐exposed; MNU, N‐methyl‐N‐nitrosourea‐treated.
Neoplastic Lesions of Male rasH2 Mice Exposed to a 20 kHz Magnetic Field
| Experiment | Experiment I | Experiment II | ||||||
|---|---|---|---|---|---|---|---|---|
| Group | Sham | MF Exp | MNU | Sham | MF Exp | MNU | ||
| Organ | Findings | Dose | 0 mT | 0.20 mT | 75 mg/kg | 0 mT | 0.20 mT | 75 mg/kg |
| No. of animals/group | 25 | 25 | 10 | 25 | 25 | 10 | ||
| Spleen | ||||||||
| Hemangioma | 0 | 0 | 0 | 1 | 0 | 0 | ||
| Hemangiosarcoma | 3 | 0 | 1 | 1 | 0 | 1 | ||
| Bone marrow | ||||||||
| Hemangioma | 0 | 1 | 0 | 0 | 0 | 0 | ||
| Thymus | ||||||||
| Hemangioma | 0 | 0 | 1 | 0 | 0 | 0 | ||
| Nasal cavity | ||||||||
| Carcinoma, squamous cell | 0 | 0 | 1 | 0 | 0 | 0 | ||
| Lung/bronchial | ||||||||
| Adenoma, bronchiolo‐alveolar | 2 | 0 | 1 | 0 | 0 | 1 | ||
| Stomach | ||||||||
| Papilloma, squamous cell | 1 | 1 | 9** | 0 | 1 | 7** | ||
| Carcinoma, squamous cell | 0 | 0 | 1 | 0 | 0 | 4** | ||
| Jejunum | ||||||||
| Adenoma | 0 | 0 | 2 | 0 | 0 | 0 | ||
| Adenocarcinoma | 0 | 0 | 2 | 0 | 0 | 1 | ||
| Ileum | ||||||||
| Adenoma | 0 | 0 | 1 | 0 | 0 | 1 | ||
| Cecum | ||||||||
| Adenocarcinoma | 0 | 0 | 0 | 0 | 0 | 1 | ||
| Rectum | ||||||||
| Adenoma | 0 | 0 | 1 | 0 | 0 | 0 | ||
| Liver | ||||||||
| Hemangioma | 1 | 0 | 0 | 0 | 0 | 0 | ||
| Urinary bladder | ||||||||
| Hemangioma | 0 | 0 | 0 | 1 | 0 | 0 | ||
| Testis | ||||||||
| Hemangioma | 0 | 0 | 0 | 1 | 0 | 0 | ||
| Epididymis | ||||||||
| Hemangioma | 1 | 0 | 0 | 0 | 0 | 0 | ||
| Musculature | ||||||||
| Hemangioma | 0 | 0 | 0 | 0 | 1 | 0 | ||
| Skin/subcutis | ||||||||
| Hemangioma | 0 | 0 | 1 | 0 | 0 | 0 | ||
| Papilloma, squamous cell | 0 | 0 | 1 | 0 | 0 | 0 | ||
| Carcinoma, squamous cell | 0 | 0 | 0 | 0 | 0 | 1 | ||
| Brain | ||||||||
| Hemangioma | 1 | 0 | 0 | 0 | 0 | 0 | ||
| All sites | [1] | [8] | [8] | |||||
| Malignant lymphoma | 1 | 8 | 8 | |||||
Sham, sham‐exposed; MF Exp, magnetic field‐exposed; MNU, N‐methyl‐N‐nitrosourea‐treated.
Numbers in square brackets are for animals examined microscopically.
*Significant difference compared to the sham‐exposed group (P < 0.01).
Neoplastic Lesions of Female rasH2 Mice Exposed to a 20 kHz Magnetic Field
| Experiment | Experiment I | Experiment II | ||||||
|---|---|---|---|---|---|---|---|---|
| Group | Sham | MF Exp | MNU | Sham | MF Exp | MNU | ||
| Organ | Findings | Dose | 0 mT | 0.20 mT | 75 mg/kg | 0 mT | 0.20 mT | 75 mg/kg |
| No. of animals/group | 25 | 25 | 10 | 25 | 25 | 10 | ||
| Mesenteric lymph node | ||||||||
| Hemangioma | 1 | 0 | 0 | 0 | 0 | 0 | ||
| Spleen | ||||||||
| Hemangioma | 0 | 0 | 0 | 0 | 0 | 1 | ||
| Hemangiosarcoma | 2 | 0 | 1 | 3 | 1 | 0 | ||
| Bone marrow | ||||||||
| Hemangioma | 0 | 1 | 1 | 1 | 0 | 0 | ||
| Thymus | ||||||||
| Hemangioma | 0 | 0 | 2 | 0 | 0 | 0 | ||
| Hemangiosarcoma | 1 | 0 | 0 | 0 | 1 | 0 | ||
| Lung/bronchial | ||||||||
| Adenoma, bronchiolo‐alveolar | 0 | 0 | 0 | 0 | 0 | 1 | ||
| Adenocarcinoma, bronchiolo‐alveolar | 0 | 0 | 0 | 0 | 1 | 0 | ||
| Tongue | ||||||||
| Papilloma, squamous cell | 0 | 0 | 1 | 0 | 0 | 0 | ||
| Salivary gland | ||||||||
| Carcinoma, squamous cell | 0 | 0 | 0 | 0 | 0 | 1 | ||
| Esophagus | ||||||||
| Papilloma, squamous cell | 0 | 0 | 0 | 0 | 0 | 1 | ||
| Stomach | ||||||||
| Papilloma, squamous cell | 0 | 3 | 8** | 0 | 0 | 10** | ||
| Carcinoma, squamous cell | 0 | 0 | 3* | 0 | 0 | 1 | ||
| Duodenum | ||||||||
| Adenoma | 0 | 0 | 1 | 0 | 0 | 0 | ||
| Jejunum | ||||||||
| Adenoma | 0 | 0 | 1 | 0 | 0 | 2 | ||
| Adenocarcinoma | 0 | 0 | 1 | 0 | 0 | 2 | ||
| Ileum | ||||||||
| Adenoma | 0 | 0 | 1 | 0 | 0 | 1 | ||
| Hemangiosarcoma | 0 | 0 | 1 | 0 | 0 | 0 | ||
| Clitoral gland | [1] | |||||||
| Carcinoma | 1 | |||||||
| Ovary | ||||||||
| Luteoma | 1 | 0 | 0 | 0 | 0 | 0 | ||
| Hemangioma | 0 | 0 | 0 | 0 | 2 | 1 | ||
| Uterus | ||||||||
| Endometrial adenoma | 0 | 0 | 0 | 0 | 0 | 1 | ||
| Hemangioma | 1 | 0 | 0 | 0 | 1 | 1 | ||
| Hemangiosarcoma | 1 | 0 | 0 | 0 | 0 | 0 | ||
| Polyp, endometrial stromal | 0 | 0 | 0 | 0 | 1 | 0 | ||
| Sarcoma, endometrial stromal | 0 | 0 | 0 | 0 | 1 | 0 | ||
| Musculature | ||||||||
| Hemangioma | 0 | 0 | 0 | 1 | 0 | 0 | ||
| Skin/subcutis | ||||||||
| Papilloma, squamous cell | 1 | 0 | 1 | 1 | 0 | 1 | ||
| Hemangiosarcoma | 0 | 1 | 0 | 0 | 1 | 0 | ||
| Harderian gland | ||||||||
| Adenoma | 1 | 1 | 0 | 0 | 1 | 0 | ||
| Brain | ||||||||
| Hemangioma | 0 | 0 | 0 | 0 | 1 | 0 | ||
| Urethra | [2] | [2] | ||||||
| Papilloma, transitional cell | 2 | 2 | ||||||
| All sites | [2] | [10] | [8] | |||||
| Malignant lymphoma | 2 | 10 | 8 | |||||
Sham, sham‐exposed; MF Exp, magnetic field‐exposed; MNU, N‐methyl‐N‐nitrosourea‐treated.
Numbers in square brackets are for animals examined microscopically.
*,**Significant difference compared to the sham‐exposed group (P < 0.05, P < 0.01, respectively).